Table 1 |
||||||
|
DNA sequence and expression divergence of human and chimpanzee promoters |
||||||
|
Promoter |
Divergence† |
Divergence TSS‡ |
Brain§ |
Liver§ |
Neuroblastoma¶ |
Cervical carcinoma¶ |
|
|
||||||
|
ACADSB |
1.4 |
3.3 |
-1.6 |
-1.3 |
-0.5* |
-0.3* |
|
C10orf10 |
1.3 |
1.8 |
ND |
4.0 |
1.4** |
0.7*** |
|
CGI-51 |
1.6 |
1.9 |
-0.4 |
-1.3 |
0.3* |
0.1 |
|
DDX17 |
1.8 |
2.0 |
-4.2 |
-4.4 |
0 |
-0.1 |
|
DHX16 |
1.5 |
0.9 |
-0.8 |
-1.7 |
0 |
0.1 |
|
HLA-DPB1 |
0.8 |
0.9 |
2.5 |
4.1 |
0.2 |
0.2 |
|
IMPA1 |
1.5 |
2.6 |
2.3 |
2.6 |
0.6* |
0.2 |
|
PCOLCE |
0.9 |
0.6 |
ND |
2.1 |
0 |
0.2 |
|
SH3BGR |
1.6 |
1.3 |
1.9 |
2.4 |
-0.8 |
-0.7*** |
|
TERF1 |
1.5 |
1.4 |
2.3 |
1.6 |
-0.7* |
0 |
|
THEM2 |
1.2 |
2.6 |
-0.5 |
-0.8 |
0.1 |
0.1 |
|
UNG |
0.6 |
0.5 |
2.5 |
1.8 |
-0.3* |
0 |
|
|
||||||
|
†Point substitutions per compared site in the whole promoter (~ 2 kbp); ‡point substitutions per compared site around the transcription start site (-200 to +20); §signal log2 ratio as determined from arrays, where positive values indicate higher expression in humans (that is, a value of 1 means twofold higher expression in humans); ¶average signal log2 ratio for the promoter activity in cell lines; *, ** and *** indicate p-values (ANOVA) < 0.05, 0.01, and 0.001, respectively. |
||||||
|
Heissig et al. Genome Biology 2005 6:R57 doi:10.1186/gb-2005-6-7-r57 |
||||||
